Monday, September 14, 2026

Imeroprubart vs. Batoclimab: Which Treatment Will Revolutionize Graves’ Disease Management?

HanAll Biopharma's Imeroprubart targets Graves' disease, showing promise with IgG suppression and user-friendly auto-injector delivery.

From Maldives to Gyeongju: How Shin Ji and Moon Won Overcame Honeymoon Disasters

Shin Ji and Moon Won's Gyeongju trip unfolds with thrills, fears, and heartfelt moments, showcasing their unique relationship dynamics.

North Korea’s Advancing AI: Potential Tool for Psychological Warfare and Human Rights Violations

North Korea's AI advancements could be used for disinformation, surveillance, and military applications, prompting calls for sanctions.

Tag: drug

North KoreaKoreaKimMilitaryAISouth Koreamarketrelationsdevelopment

Navigating FDA Challenges: How SK Biopharmaceuticals Plans to Move Forward with Opacalim

SK Biopharm will maintain its development and commercialization plans for epilepsy drug candidate Opacalim despite FDA's partial clinical hold.

SK Biopharm’s Epilepsy Drug Trial Partially Halted in U.S., New Enrollment Suspended

SK Biopharm's U.S. trials of epilepsy drug candidate opicopalim have been partially placed on hold by the FDA, temporarily stopping new enrollment while existing patients continue treatment.

Korean Obesity Drug Set to Launch Next Month as Hanmi’s Efe Targets Market

Hanmi Pharmaceutical plans to launch its domestically developed GLP-1 obesity drug Efe as early as next month, with Korean clinical data, safety and domestic production as key selling points.

What Led to the Supreme Court’s Decision on Medical Liability in a Child’s Severe Drug Reaction?

A Supreme Court ruling states that doctors cannot be held criminally liable for not diagnosing drug allergy syndrome early in patients with liver failure.

Unlocking UAE: How Korean Biotech Firms Can Navigate Regulatory Hurdles in 2026

The Ministry of Food and Drug Safety will facilitate communication between local regulatory authorities and Korean bio companies for UAE market entry.

SK Biopharm’s Bold Move: How MD Expertise is Shaping Global Drug Development in 2026

SK Biopharm is enhancing its global competitiveness in drug development by establishing a specialized R&D system for new drug candidates.

Curocell’s ‘Lymcato’ Clears Review for National Health Insurance Coverage

Curocell’s CAR-T therapy Lymcato has passed the Health Insurance Review and Assessment Service’s drug reimbursement review, accelerating its path toward national health insurance coverage this year.

Pharos iBio and Kolon Pharmaceutical Expand Joint Development of Lung Cancer Drug

Pharos iBio and Kolon Pharmaceutical are stepping up development of PHI-701, a next-generation EGFR inhibitor targeting patients who have developed resistance to existing targeted lung cancer treatments.

Revolutionary Liver Cancer Treatment: How Rivoceranib + Camrelizumab Outperforms Sorafenib in Young Patients

HLB's liver cancer drug combo shows consistent efficacy across all age groups.

How Kangstem Biotech’s Organoid Technology is Revolutionizing Skin Disease Treatment with Global Pharma Partnerships

Kangstem Biotech accelerates global expansion by signing a drug evaluation contract with a major pharmaceutical company for skin immune diseases.

SK Biopharmaceuticals’s Opakalim: Targeting U.S. Launch in 2029—How Effective Is It at Suppressing Seizures?

SK Biopharmaceuticals takes a significant step with its epilepsy drug candidate Opakalim (BHV-7000) as it addresses the Xcopri one-tool challenge.

SK Biopharmaceuticals Acquires Opacalim: What This 795 Million USD Epilepsy Drug Deal Means for Patients

SK Biopharmaceuticals has acquired a new epilepsy drug candidate from Biohaven Bioscience, enhancing its portfolio in neurology.

Daiwoong Pharmaceuticals Secures U.S. Patent for Revolutionary Anti-Aging mRNA Delivery Technology

Daewoong Pharmaceutical is close to securing a U.S. patent for a key drug delivery technology for developing anti-aging treatments.

SK Biopharmaceuticals Secures 795 Million USD License for Groundbreaking Epilepsy Drug Opacalim – What You Need to Know

SK Biopharmaceuticals acquires epilepsy drug candidate from Biohaven for 795 million USD, enhancing its global biotech portfolio.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.